Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 3/20 | 0.50 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.43 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482909 | 0.90 | SRC (0.52) | EPHB4ZAP70KDRAURKBIGF1R | |
| SCHEMBL6479263 | 0.86 | SYK (0.57) | EPHB4ZAP70KDRJAK3ABL1 | |
| SCHEMBL4946510 | 0.82 | EPHB4 (0.69) | EPHB4KDRAURKBIGF1RJAK2 | |
| SCHEMBL6483193 | 0.78 | KDR (0.57) | EPHB4KDRJAK3FLT3DAPK3 | |
| SCHEMBL6479597 | 0.73 | KDR (0.57) | EPHB4KDRAURKBIGF1RJAK2 | |
| SCHEMBL17630988 | 0.70 | FGFR3 (0.53) | KDRIGF1RJAK2TBK1FGFR1 | |
| SCHEMBL12185363 | 0.70 | ZAP70 (0.73) | ZAP70IGF1RJAK2JAK3FLT3 | |
| SCHEMBL14214558 | 0.69 | ZAP70 (0.73) | ZAP70FLT3TBK1PRKD3LCK | |
| SCHEMBL13325996 | 0.69 | PTK2 (0.62) | EPHB4KDRAURKBIGF1RJAK2 | |
| SCHEMBL6493240 | 0.69 | KDR (0.56) | EPHB4KDRIGF1RJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | EPHB4 2420/4885ZAP70 2792/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.